Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
$40.76
-$0.78(-1.91%)
At close: 4:00 PM EST
$40.76
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$26.74 - $44.23
Previous CloseN/A
Volume41.45K
Average Volume (3M)797.39K
Market Cap
$3.15B
Enterprise Value$2.73B
Total Cash (Recent Filing)$462.27M
Total Debt (Recent Filing)$8.33M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 26, 2026EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding77,275,000
10 Day Avg. Volume829,534
30 Day Avg. Volume797,395
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)4.04
Price to Sales (P/S)0.00
P/FCF Ratio-16.55
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue363.72
Enterprise Value/Gross Profit-38.87
Enterprise Value/Ebitda-8.21
Forecast
1Y Price Target
$55.15Price Target Upside35.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.26
Revenue Forecast (FY)$7.56M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe enrollment completion of the Phase 3 X-TOLE2 study marks a key milestone for azetukalner.
Financial PositionThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.
Pipeline ExpansionXenon Pharmaceuticals hosted an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
Bears Say
Competitive LandscapePotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy in 1H26.
Investment NeedsFurther investment and patience are required for azetukalner, despite its strong Phase 2b data and differentiated mechanism.
Market VolatilityShares are volatile after market, likely due to management commentary that timing will be refined despite the 'early 2026' guidance.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $44.23 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $3.15B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Feb 26, 2026 which is in 102 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Nov 03, 2025. The company reported -$1.15 earnings per share for the quarter, beating the consensus estimate of -$1.152 by $0.002.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.19.
How many shares outstanding does Xenon have?
Xenon has 77,275,000 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.15 in its last earnings report, beating expectations of -$1.152. Following the earnings report the stock price went down -4.937%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.15 (35.30% Upside)
$55.15 (35.30% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.37%
12-Months-Change
Fundamentals
Return on Equity
-45.14%
Trailing 12-Months
Asset Growth
-27.28%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Xenon's late-stage and early-stage clinical programs, particularly for azetukalner in epilepsy and neuropsychiatric disorders. Financially, the company is well-positioned to support its operations and pipeline development. While challenges exist, such as increased competition and screening hurdles, the positive advancements and robust financial health contribute to an overall optimistic outlook.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$55.15
▲(35.30% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.14% Insiders
29.43% Mutual Funds
0.10% Other Institutional Investors
64.21% Public Companies and
Individual Investors